1. Meaning and concept

Biotech Addiction Treatment Governance refers to the legal, ethical, medical, and institutional framework governing the development, approval, administration, monitoring, and oversight of biotechnology-based interventions used to treat substance-use disorders and addictive behaviours.

It is a useful interdisciplinary framework rather than the name of a single, established legal doctrine. Its purpose is to ensure that scientific advances in addiction treatment are safe, effective, evidence-based, accessible, and consistent with human rights.

Biotechnology may support addiction treatment through pharmacological innovations, biological diagnostics, pharmacogenomics, and research into neurological mechanisms underlying dependence. However, not every addiction treatment is biotechnology: conventional counselling, peer support, and many established medicines fall outside narrower definitions of biotechnology.

SGT BIOTECH

1. Biotechnological research

Development of novel medicines, biological markers, genetic-response studies, and research into the biological mechanisms of addiction.

BmK Defensins: Venom-Derived Peptides in Neuro Drug Research

2. Clinical treatment and safety

Evidence-based treatment, appropriate prescribing, clinical trials, adverse-event reporting, and long-term monitoring.

Medication-Assisted Treatment: 5 Powerful Benefits in 2025

3. Rights-based governance

Informed consent, privacy, freedom from unlawful detention, non-discrimination, independent review, and access to remedies.

The central legal question is: How can the law encourage innovative addiction treatments without allowing patients to be coerced, exploited, discriminated against, or exposed to unreasonable biological risks?

2. Objectives of the governance framework

The framework can be organised around seven objectives:

Patient safety: Prevent unsafe drugs, inadequately tested interventions, misleading claims, and negligent clinical practice.

Informed consent: Ensure that patients understand the treatment, its risks, alternatives, uncertainties, and possible consequences of refusing it.

Scientific integrity: Require appropriate evidence before experimental interventions are marketed or used in clinical practice.

Privacy and genetic-data protection: Protect biological samples, genomic information, and sensitive addiction-treatment records.

Freedom and dignity: Prevent unjustified confinement, forced procedures, and punishment disguised as rehabilitation.

Accountability: Establish clear responsibility for manufacturers, researchers, doctors, hospitals, rehabilitation centres, and regulators.

Equitable access: Prevent unjustified exclusion based on disability, socioeconomic status, criminal history, or participation in evidence-based medication treatment.

These objectives interact. For example, a treatment might be scientifically promising but still be unlawful if it is administered without legally valid consent or without the required regulatory authorisation.

3. Legal framework in India

India is a particularly relevant jurisdiction for this topic because addiction treatment involves the interaction of constitutional rights, drug regulation, mental healthcare legislation, clinical research rules, and professional responsibility.

A. Constitutional protections

The Constitution of India provides the foundation for regulating biotechnology-based addiction treatment.

A patient’s addiction does not automatically remove their constitutional protections. Nor does a family member’s concern, by itself, establish legal authority to confine a competent adult or compel experimental treatment.

B. Mental Healthcare Act, 2017

The Mental Healthcare Act, 2017 is central to the governance of addiction treatment where its provisions apply.

Section 4 — Capacity to make treatment decisions. Capacity is assessed by reference to whether the person can understand relevant information, appreciate reasonably foreseeable consequences, or communicate a decision. A decision considered unwise by others does not, by itself, establish incapacity.

IndiaCode

Section 86 — Independent admission and treatment. An eligible adult who independently seeks admission must meet the statutory conditions. Treatment requires informed consent, and discharge rights are subject to the Act's applicable provisions.

IndiaCode

Sections 89–90 — Supported admission. These provisions establish statutory conditions and safeguards for specified admissions involving people with mental illness and high support needs. They do not create a general power to confine anyone who uses alcohol or drugs.

IndiaCode+1

The critical distinction is between a person who needs treatment and a person who legally qualifies for supported admission. The two are not automatically the same.

C. Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019

The Central Drugs Standard Control Organisation (CDSCO), operating under the relevant statutory framework, oversees matters including new-drug approval and clinical-trial permissions.

DGHS Health Ministry+1

The New Drugs and Clinical Trials Rules, 2019 establish requirements governing clinical trials of new or investigational drugs, including prior regulatory permission, ethics committee approval, and compliance with applicable research safeguards.

IndiaCode+1

For biotechnology-based addiction treatments, this means that a promising laboratory result is not enough to justify unrestricted clinical use.

A developer or institution must establish which regulatory pathway applies to the specific product or intervention. A gene-based intervention, a biological diagnostic, and a conventional medicine may have different regulatory requirements.

Official references:

CDSCO — New Drugs and Clinical Trials Rules

CDSCO — Ethics Committee oversight

D. Narcotic Drugs and Psychotropic Substances Act, 1985

The Narcotic Drugs and Psychotropic Substances Act, 1985 is also relevant.

Section 64A provides a conditional immunity mechanism for qualifying addicts charged with specified offences who voluntarily seek and undergo treatment, subject to statutory conditions.

Section 71 empowers the government to establish or recognise centres for the identification, treatment, education, aftercare, rehabilitation, and social reintegration of addicts, subject to the Act.

These provisions demonstrate that addiction law is not exclusively punitive. However, statutory immunity and treatment-centre powers should not be interpreted as blanket permission for involuntary biotechnology procedures or unlawful confinement.

4. Case laws and judicial precedents

The following cases are especially useful. Some concern addiction treatment directly, while others establish broader constitutional or clinical-research principles relevant by analogy. They should not be mistaken for decisions specifically approving biotechnology-based addiction therapies.

Case 1: Ashish Sharma v. State of NCT of Delhi & Ors. (2024)

Delhi High Court · W.P. (CRL) 2196/2024 · 12 August 2024

Facts and issue: The case concerned a habeas corpus petition involving a person allegedly confined against his wishes in a de-addiction centre. The proceedings raised questions about whether admission was genuinely voluntary and whether statutory safeguards were being observed.

Decision and significance: The Delhi High Court directed independent medical assessment and regulatory inspections to address concerns about involuntary detention and compliance with the Mental Healthcare Act, 2017.

Cornelia – Judgment+1

Legal principle: A de-addiction centre cannot treat the label of rehabilitation as sufficient justification for restricting a person's liberty. The legality of admission and continued detention must be assessed under the applicable law.

Application to biotechnology: A centre should not use an experimental drug, implant, biological intervention, or other invasive procedure as a condition of release or as a substitute for legally required consent.

Case 2: Dr. Vijay Verma v. Union of India (2018)

Delhi High Court · 1 June 2018, as referenced in the statutory case-law material

This decision is identified in the available case-law material as relevant to Section 89 of the Mental Healthcare Act, 2017, particularly the statutory procedure and oversight required for supported admission.

IndiaCode

Legal significance: A person cannot lawfully be deprived of liberty merely because someone else believes that treatment is desirable. The statutory conditions and safeguards governing supported admission must be followed.

Application: Before an addiction-treatment facility imposes restrictive care, it must establish a lawful basis for the admission and comply with the relevant procedural requirements. A family's request alone is not a substitute for the statutory process.

Research note: The precise judgment text should be consulted before relying on this case for a specific factual proposition or quoting a judicial holding in formal litigation.

Case 3: Common Cause v. Union of India (2018)

Supreme Court of India · (2018) 5 SCC 1

Subject: Constitutional autonomy, dignity, and end-of-life medical decision-making.

Legal significance: The Supreme Court recognised important aspects of personal autonomy and dignity in medical decision-making, including the legal framework for advance directives and withdrawal of life-sustaining treatment in specified circumstances.

Relevance to biotech addiction treatment: The decision provides a broader constitutional foundation for respecting a person's wishes concerning medical care. It does not, however, establish a specific right to refuse every addiction intervention regardless of the circumstances or applicable law.

Its relevance is strongest where a proposed treatment involves invasive intervention, substantial risks, or disputes over the patient's wishes.

Case 4: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts and issue: The case concerned medical consent and a procedure performed beyond the scope of the consent given by the patient.

Legal principle: Valid consent must relate to the treatment actually undertaken. Consent to one procedure does not automatically authorise a materially different procedure, except where a recognised legal exception applies.

Application: Consent to enter an addiction-treatment programme should not automatically be treated as consent to genetic testing, an invasive biological procedure, or an experimental intervention.

The provider must explain the proposed intervention, relevant risks, alternatives, and the nature of the consent being sought. The case is a general medical-consent precedent rather than an addiction-specific ruling.

Case 5: K.S. Puttaswamy v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Subject: The constitutional right to privacy.

Legal principle: Privacy is a constitutionally protected right under Article 21 and Part III of the Constitution, subject to the applicable constitutional requirements for restrictions.

Application to biotech governance: Genetic information, neural measurements, biological samples, and detailed addiction-treatment records can reveal deeply personal information. Their collection and use should have an appropriate legal basis and safeguards proportionate to the purpose.

For example, a clinic should not disclose a patient's genetic predisposition to addiction to an employer or insurer merely because the clinic possesses that information.

The judgment supplies a constitutional privacy foundation; the precise obligations for any particular data-processing activity depend on the applicable legislation and circumstances.

Case 6: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India · (2005) 6 SCC 1

Subject: Medical negligence and professional accountability.

Legal significance: The Supreme Court examined the standards governing criminal liability for medical negligence and distinguished criminal negligence from every error or adverse medical outcome.

Application to biotech addiction treatment:

A clinician who administers a biological treatment without adequate professional competence, ignores recognised safety precautions, or acts with the degree of negligence required by the applicable liability standard may face legal consequences.

The case also helps distinguish different kinds of responsibility:

Civil liability for compensable injury.

Criminal liability where the applicable legal threshold is met.

Professional disciplinary action.

Regulatory consequences for unlawful or unsafe treatment.

An adverse outcome alone does not automatically establish negligence. The standard of care, causation, evidence, and applicable legal test must be assessed.

Case 7: Marshall v. United States (1974)

United States Supreme Court · 414 U.S. 417 (1974)

Subject: Statutory eligibility for rehabilitative commitment instead of imprisonment for certain narcotics offenders.

Decision: The Court upheld the statutory exclusion of certain repeat felony offenders from the rehabilitative commitment scheme at issue, finding no violation of due process or equal protection under the circumstances.

LII / Legal Information Institute

Application: This case illustrates that governments may design statutory eligibility criteria for particular treatment programmes, but those criteria remain subject to the governing constitutional framework.

It does not authorise forced biotechnology treatment, nor does it establish that people with addiction can generally be denied appropriate healthcare because of their criminal history.

Comparative case-law summary

The cases do not all address biotechnology directly. Their value lies in the legal principles they establish for consent, liberty, privacy, and medical responsibility.

5. Principal areas of biotechnology governance

A. Regulatory approval and scientific validity

A biotechnology-based treatment should undergo appropriate preclinical assessment, clinical evaluation, and regulatory scrutiny before routine use where required by law.

Governance should address:

Whether the intervention has a scientifically supported therapeutic purpose.

Whether its benefits outweigh its known and reasonably foreseeable risks.

Whether clinical trials have received required approvals.

Whether study participants receive adequate information and protection.

Whether adverse effects and unexpected safety signals are reported.

Whether marketing claims accurately reflect the evidence.

India's New Drugs and Clinical Trials Rules, 2019 are particularly relevant where the intervention qualifies as a new or investigational drug. Other products may fall under different regulatory regimes.

IndiaCode+1

B. Informed consent and bodily autonomy

Consent is one of the most important governance requirements.

A valid process should explain:

The nature and purpose of the treatment.

Its expected benefits and material risks.

Available alternatives, including non-biological treatment options.

What remains scientifically uncertain.

How personal and biological information will be used.

Whether the treatment can be stopped and what the consequences may be.

Consent must be voluntary and appropriate to the particular intervention. Agreement to ordinary addiction treatment is not blanket authorisation for experimental genetic modification or invasive neural intervention.

Research participation and ordinary clinical care must also be distinguished: permission to receive a treatment does not necessarily constitute consent to participate in research.

C. Genetic and biological privacy

Biotechnology can create sensitive information about a person's susceptibility to substance dependence, treatment response, or other biological characteristics.

A robust governance framework should require:

Purpose limitation and appropriate access controls.

Secure storage and controlled sharing of biological samples.

Transparent rules for secondary research use.

Appropriate retention and deletion policies.

Protection against unauthorised disclosure.

Independent oversight where research creates heightened risks.

A genetic risk marker must not automatically be treated as proof that someone has an addiction, will relapse, or is incapable of making decisions.

D. Algorithmic treatment and biological risk scoring

Suppose a rehabilitation provider uses a genetic test or predictive model to estimate the likelihood of relapse.

A lawful and responsible framework should examine the test's validity, accuracy, limitations, and potential for discrimination. Patients should not be denied treatment or subjected to restrictive conditions solely because an inadequately validated algorithm predicts future addictive behaviour.

Where an automated assessment affects access to care or personal liberty, governance should include meaningful human review, appropriate explanations, and a mechanism to challenge inaccurate findings.

E. Experimental neural or gene-based interventions

Interventions that alter biological functioning raise additional ethical and legal concerns, especially if their effects may be long-lasting or difficult to reverse.

Governance should assess:

Reversibility and the duration of effects.

Risks of unintended biological changes.

Long-term physical and psychological outcomes.

The patient's continuing ability to make independent decisions.

The possibility of coercion by family members, employers, prisons, or institutions.

Whether the proposed intervention is authorised for the intended purpose.

A treatment's potential effectiveness does not, by itself, justify overriding bodily autonomy.

6. Institutional accountability and liability

Responsibility should be allocated according to each participant's role.

The precise liability depends on the governing statute, the actor's conduct, the applicable standard of care, and proof of causation. An institution is not automatically liable for every adverse event, just as a manufacturer's regulatory approval does not necessarily eliminate every possible product-liability claim.

Remedies for violations

Depending on the facts and applicable law, potential remedies include:

Complaints to the relevant health or drug regulator.

Professional disciplinary proceedings.

Compensation for legally established injury.

Judicial review of unlawful administrative decisions.

Habeas corpus proceedings where detention is unlawful.

Constitutional remedies for violations of enforceable fundamental rights.

Suspension of a trial or treatment programme where legally justified.

7. Hypothetical case study

Consider an Indian biotechnology company that develops an experimental biological intervention intended to reduce severe opioid dependence. A private rehabilitation centre offers the intervention to patients and tells their families that it is a permanent cure.

A patient agrees to enter the centre but refuses the experimental intervention. The centre nevertheless administers it and prevents the patient from leaving.

Several independent legal questions arise.

Issue 1: Regulatory compliance

Was the intervention authorised for the proposed use, and were the required clinical-trial or other regulatory approvals obtained?

Issue 2: Consent

Consent to enter the centre does not automatically amount to consent to an experimental biological procedure.

Issue 3: Liberty

The centre must establish a lawful basis for any restriction on the patient's freedom and follow the applicable statutory safeguards.

Issue 4: Accountability

Regulators and courts may examine the conduct of the company, investigators, clinicians, and centre separately, depending on their respective roles.

The case could engage the principles in Samira Kohli, Puttaswamy, Jacob Mathew, and Ashish Sharma, as well as the applicable drug and mental-healthcare legislation.

The legal outcome would depend on the evidence and precise statutory requirements. The central point is that a therapeutic objective does not excuse unlawful experimentation or detention.

8. Proposed model for effective governance

A comprehensive Biotech Addiction Treatment Governance framework should have six connected layers.

Layer 1 — Scientific validation

Evidence, safety, efficacy, and transparent uncertainty

Layer 2 — Regulatory authorisation

Product approval, clinical-trial permission, and ethics review

Layer 3 — Patient autonomy

Informed consent, capacity assessment, and lawful admission

Layer 4 — Data and fairness

Privacy, cybersecurity, non-discrimination, and human oversight

Layer 5 — Continuing monitoring

Adverse-event reporting, follow-up, and independent inspections

Layer 6 — Accountability and remedies

Audits, complaints, compensation where available, and judicial review

These layers should operate throughout the intervention's lifecycle, from laboratory research to clinical deployment and post-treatment monitoring.

9. Critical legal challenges

The principal challenges are not merely technological. They concern how institutions use scientific knowledge and how the law responds when biological interventions affect fundamental interests.

First, the treatment-versus-control problem: a therapy intended to help a patient may become a means of controlling behaviour if consent and discharge safeguards are ignored.

Second, the uncertainty problem: genetic and neurological predictors may be probabilistic rather than conclusive. Treating predictions as facts can create unjustified restrictions.

Third, the inequality problem: expensive therapies may be accessible only to wealthy patients, while disadvantaged populations face coercive or inferior alternatives.

Fourth, the accountability gap: several entities may participate in a single treatment, making it difficult to identify who was responsible for an injury or unlawful decision.

Fifth, the long-term monitoring problem: an intervention may appear safe in short-term studies while its longer-term effects remain uncertain.

An effective framework must therefore combine scientific review with enforceable rights, independent oversight, transparent decision-making, and accessible remedies.

10. Conclusion

Biotech Addiction Treatment Governance is best understood as a proposed legal and institutional framework for ensuring that biotechnology-based addiction treatment is scientifically justified, lawfully administered, ethically acceptable, and accountable.

In India, the constitutional guarantees of dignity, liberty, equality, and privacy interact with the Mental Healthcare Act, 2017, the NDPS Act, 1985, and the drug-regulatory framework governing new medicines and clinical trials.

The most important legal principles are:

Addiction does not automatically extinguish a person's rights.

Consent to one form of treatment does not authorise every subsequent intervention.

Experimental biotechnology must satisfy the regulatory requirements applicable to the particular intervention.

Predictive biological information must not be used as an unquestionable substitute for individual assessment.

Rehabilitation centres must comply with the law governing admission, treatment, and discharge.

Manufacturers, clinicians, researchers, institutions, and regulators must be held accountable according to their respective legal duties.

The overarching principle is that biotechnology should expand the safe and effective options available to people experiencing addiction, not become a justification for coercion, discrimination, or the unnecessary restriction of personal liberty.

Academic note: “Biotech Addiction Treatment Governance” is a useful analytical heading, not a recognised standalone cause of action or settled doctrine. For formal legal writing, each proposition should be linked to the precise statutory provision and verified judgment applicable to the facts and jurisdiction.